Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing antibody-based therapies for rare blood disorders. Its lead programs include sutacimig and HMB-002, and the company operates through a Delaware holding-company structure with research and development activities centered on advancing these product candidates through clinical testing.

— Hemab Therapeutics Holdings, Inc.
%
Clinical-stage product candidates0% Antibody-based drug candidates being developed for rare hematology indications.
Research and preclinical pipeline0% Discovery-stage programs intended to expand the company’s therapeutic portfolio.
Clinical development services0% Internal development work covering trials, regulatory preparation, and CMC activities.
Future product commercialization0% Potential sales of approved therapies and related market access activities.
Collaboration and licensing income0% Potential non-product revenue from partnerships, sublicenses, or licensing deals.

Hemab does not yet sell approved products, so its near-term counterparties are primarily clinical investigators, trial...

  • Clinical investigators and trial sitesprimary

    They run Hemab’s studies and generate the data needed for regulatory approval.

  • Regulatory agenciesprimary

    They review trial, safety, and manufacturing packages before any approval.

  • Contract manufacturers and suppliersprimary

    They provide biologics manufacturing capacity and clinical supply support.

  • Pharma collaboration partnerssecondary

    They may license, co-develop, or commercialize product candidates.

  • Specialty hematology providers and payorsemerging

    They would buy and reimburse approved therapies for rare bleeding disorders.

Hemab Therapeutics Holdings is incorporated in Delaware and operates as a U.S.-based public biopharmaceutical company,...

  • •U.S.-based holding company incorporated in Delaware
  • •Historical operating roots in Hemab ApS and related subsidiaries
  • •Clinical development and manufacturing can involve multiple countries
  • •No product revenue disclosed, so no country revenue mix is available
  • •Geographic exposure is driven by trials, suppliers, and IP protection

Hemab’s strategy is to advance its lead programs through later-stage clinical trials, secure regulatory approvals, and...

01
Advance lead programs through clinical developmentshort-term

Clinical proof-of-concept and later-stage data are required for approval and value creation.

02
Secure manufacturing and supply chain readinessshort-term

Biologics require reliable CMO capacity and controlled supply to support trials and launch.

03
Expand the pipeline and partnership optionsmedium-term

A broader portfolio and external collaborations can diversify risk and funding sources.

04
Build commercialization infrastructuremedium-term

Approved therapies will require sales, medical affairs, and distribution capabilities.

Hemab is a clinical-stage company with no approved products, so its value depends heavily on successful development,...

critical

Clinical development failure or delay

Sutacimig and HMB-002 are the company’s only clinical-stage candidates, so setbacks would materially impair value.

Scope
Lead programs
Materiality
high
high

Manufacturing and supply chain disruption

Biologics production is technically complex and vulnerable to contamination, raw material, and CMO failures.

Scope
Clinical and future commercial supply
Materiality
high
high

Funding and dilution risk

The company expects to finance operations through external capital and partnerships until revenue exists.

Scope
Corporate funding
Materiality
high
medium

Competitive and patent risk

Existing therapies and competing development programs could reduce pricing power or market share.

Scope
Rare hematology markets
Materiality
medium
medium

Third-party execution risk

Clinical sites, manufacturers, and distributors must perform to protocol and regulatory standards.

Scope
Outsourced operations
Materiality
medium
Research and development expense accruals
Affects operating expense timing and period-to-period comparability
Warrant accounting
Can affect equity balances and, depending on terms, earnings volatility
Corporate reorganization accounting
Affects comparability of historical financial statements and equity presentation
Stock-based compensation
Affects reported operating loss and diluted share calculations

Emmaus Life Sciences, Inc.

EMMA · Pharmaceutical Preparations

OmniAb, Inc.

OABIW · Services-Commercial Physical & Biological Research

AMICUS THERAPEUTICS, INC.

Pharmaceutical Preparations

ANAPTYSBIO, INC

ANAB · Pharmaceutical Preparations

Papa Medical Inc.

Cigarettes

IMAC Holdings, Inc.

BACK · Services-Specialty Outpatient Facilities, NEC

: 16.6.2026